DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

E-7820

Generic Name: E-7820

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₂N_₄O_₂S

CAS Number: 289483-69-8

Unique Ingredient Identifier: TVH5K7949N

Overview

E7820 has been investigated for the treatment of Colon Cancer and Rectal Cancer.

Background

E7820 has been investigated for the treatment of Colon Cancer and Rectal Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

Phase 2

Active, not recruiting

Posted: 2021/08/27

Sponsor:Memorial Sloan Kette...

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Phase 1

Completed

Posted: 2013/01/23

Sponsor:Eisai Inc.

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Phase 1

Terminated

Posted: 2011/05/04

Sponsor:Eisai Inc.

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Phase 1

Terminated

Posted: 2010/05/31

Sponsor:Eisai Inc.

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Phase 1

Completed

Posted: 2004/03/05

Sponsor:Eisai Inc.

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Eisai's E7820 Shows Promise in Shrinking Tumors with HRR Deficiency

8 months ago

Eisai's E7820 demonstrated tumor shrinkage in patient-derived xenograft models of bile duct and uterine cancers, suggesting potential efficacy in these tumor types.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy